The current PSMA antibody-MMAE conjugate used clinically for prostate cancer treatment has a low DAR value of approximately 3.5 and when used in prostate cancer LNCaP cell lines, resulted in a significant difference in the IC50 value of this conjugate between the LNCaP cell line and a control cell line model [61]. This evidence concerns the gene FOLH1 and prostate carcinoma.